Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/1839
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chisholm, D. | en_US |
dc.contributor.author | Gureje, O. | en_US |
dc.contributor.author | Saldivia, S. | en_US |
dc.contributor.author | Villalon Calderon, M. | en_US |
dc.contributor.author | Wickremasinghe, R. | en_US |
dc.contributor.author | Mendis, N. | en_US |
dc.contributor.author | Ayuso-Mateos, J. L. | en_US |
dc.contributor.author | Saxena, S. | en_US |
dc.date.accessioned | 2014-10-29T09:26:48Z | - |
dc.date.available | 2014-10-29T09:26:48Z | - |
dc.date.issued | 2008 | en_US |
dc.identifier.citation | Bulletin of the World Health Organization. 2008; 86(7): pp.542-51 | en_US |
dc.identifier.issn | 0042-9686 (Print) | en_US |
dc.identifier.issn | 1564-0604 (Electronic) | en_US |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/1839 | - |
dc.description | Indexed in MEDLINE | - |
dc.description.abstract | OBJECTIVE: Schizophrenia is a highly disabling disease and is costly to treat. We set out to establish what are the most cost-effective interventions applicable to developing regions and countries. METHODS: Analysis was undertaken at the level of three WHO subregions spanning the Americas, Africa and South-East Asia, and subsequently in three member states (Chile, Nigeria and Sri Lanka). A state transition model was used to estimate the population-level health impact of older and newer antipsychotic drugs, alone or in combination with psychosocial intervention. Total population-level costs (in international dollars or local currencies) and effectiveness (measured in disability-adjusted life years averted) were combined to form cost-effectiveness ratios. FINDINGS: The most cost-effective interventions were those using older antipsychotic drugs combined with psychosocial treatment, delivered via a community-based service model (I$ 2350-7158 per disability-adjusted life year averted across the three subregions, I$ 1670-3400 following country-level contextualisation within each of these subregions). The relative cost-effectiveness of interventions making use of newer, "atypical" antipsychotic drugs is estimated to be much less favourable. CONCLUSION: By moving to a community-based service model and selecting efficient treatment options, the cost of substantially increasingtreatment coverage is not high (less than I$ 1 investment per capita). Taken together with other priority-setting criteria such as disease severity, vulnerability and human rights protection, this study suggests that a great deal more could be done for persons and families living under the spectre of this disorder | - |
dc.publisher | World Health Organization | en_US |
dc.title | Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis | en_US |
dc.type | Article | en_US |
dc.identifier.department | Public Health | en_US |
dc.creator.corporateauthor | World Health Organization | en_US |
Appears in Collections: | Journal/Magazine Articles |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.